Zacks Investment Research upgraded shares of Myovant Sciences Ltd (NASDAQ:MYOV) from a sell rating to a hold rating in a report released on Tuesday.

According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “

A number of other brokerages have also commented on MYOV. JMP Securities reissued an outperform rating and set a $25.00 price target (up from $23.00) on shares of Myovant Sciences in a research note on Wednesday, October 4th. Robert W. Baird reissued a buy rating and set a $20.00 price target on shares of Myovant Sciences in a research note on Wednesday, October 4th. Cowen and Company reissued a buy rating on shares of Myovant Sciences in a research note on Tuesday, October 3rd. Finally, Evercore ISI assumed coverage on Myovant Sciences in a research note on Wednesday, August 16th. They set an outperform rating for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $20.00.

Shares of Myovant Sciences (NASDAQ MYOV) traded up 2.81% during trading on Tuesday, hitting $13.91. The company had a trading volume of 16,682 shares. The stock’s market capitalization is $846.34 million. The firm’s 50 day moving average is $14.00 and its 200-day moving average is $14.00. Myovant Sciences has a 52 week low of $9.92 and a 52 week high of $18.85.

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/20/myovant-sciences-ltd-myov-lifted-to-hold-at-zacks-investment-research.html.

A number of institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP bought a new position in Myovant Sciences during the second quarter valued at approximately $648,000. RA Capital Management LLC raised its position in Myovant Sciences by 19.6% during the second quarter. RA Capital Management LLC now owns 2,807,550 shares of the company’s stock valued at $32,848,000 after purchasing an additional 459,128 shares during the period. Goldman Sachs Group Inc. purchased a new stake in Myovant Sciences during the second quarter valued at approximately $174,000. Voya Investment Management LLC raised its position in Myovant Sciences by 5.4% during the second quarter. Voya Investment Management LLC now owns 421,397 shares of the company’s stock valued at $4,931,000 after purchasing an additional 21,478 shares during the period. Finally, OxFORD Asset Management LLP raised its position in Myovant Sciences by 15.4% during the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after purchasing an additional 3,971 shares during the period.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.